Retinal PhysicianThe Evolution of AREDS

🎓 Expert Commentary / Peer Perspective

AREDS2 established lutein/zeaxanthin over beta-carotene and demonstrated a 25% reduction in progression to advanced AMD in high-risk patients. The National Eye Institute is now developing a prospective AREDS3 study, with post hoc analyses suggesting antioxidant and carotenoid supplementation may slow noncentral geographic atrophy progression toward the fovea — findings requiring prospective validation.

Clinical Considerations:

• AREDS2 does not target complement dysregulation or chronic inflammation, now recognized as central AMD drivers
• Meso-zeaxanthin, absent from AREDS2, may enhance macular pigment optical density when combined with lutein and zeaxanthin; outcomes data remain limited
• Mitochondrial support agents (coenzyme Q10, nicotinamide, NAD+ precursors) are hypothesis-generating; no robust AMD-specific clinical trials have been completed
• Genotype-guided supplementation based on complement pathway variants is under investigation but not yet standard practice

Practice Applications:

• Continue recommending AREDS2 for appropriate patients (intermediate AMD or advanced disease in one eye); no alternative has demonstrated superior outcomes in randomized trials
• Recognize that omega-3 fatty acids showed no benefit in AREDS2 and remain unvalidated as AMD supplementation components
• Monitor the AREDS3 trial design and enrollment as the next prospective benchmark for supplementation strategy evolution
• Interpret emerging mitochondrial and complement-targeted nutritional approaches as investigational, not yet ready for clinical recommendation